ECSP22026797A - Composiciones y métodos para el tratamiento de infecciones virales - Google Patents

Composiciones y métodos para el tratamiento de infecciones virales

Info

Publication number
ECSP22026797A
ECSP22026797A ECSENADI202226797A ECDI202226797A ECSP22026797A EC SP22026797 A ECSP22026797 A EC SP22026797A EC SENADI202226797 A ECSENADI202226797 A EC SENADI202226797A EC DI202226797 A ECDI202226797 A EC DI202226797A EC SP22026797 A ECSP22026797 A EC SP22026797A
Authority
EC
Ecuador
Prior art keywords
viral infections
compositions
treatment
methods
binding peptide
Prior art date
Application number
ECSENADI202226797A
Other languages
English (en)
Inventor
James Balkovec
Thomas Brady
Leslie Tari
Simon Doehrmann
Jason Cole
Alain Noncovich
Allen Borchardt
Wanlong Jiang
Quyen-Quyen Do
Zhi-yong CHEN
Thanh Lam
Daniel Bensen
Original Assignee
Cidara Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cidara Therapeutics Inc filed Critical Cidara Therapeutics Inc
Publication of ECSP22026797A publication Critical patent/ECSP22026797A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Las composiciones y métodos para el tratamiento de infecciones virales incluyen conjugados que contienen inhibidores de neuraminidasa viral (por ejemplo, zanamivir, peramivir o análogos de estos) unidos a un monómero de Fc, un dominio Fc y un péptido de unión a Fc, una proteína albúmina o péptido de unión a albúmina. En particular, los conjugados pueden utilizarse en el tratamiento de infecciones virales (por ejemplo, infecciones virales de influenza).
ECSENADI202226797A 2019-09-06 2022-04-05 Composiciones y métodos para el tratamiento de infecciones virales ECSP22026797A (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201962897036P 2019-09-06 2019-09-06
US201962941405P 2019-11-27 2019-11-27
US201962948143P 2019-12-13 2019-12-13
US202062959857P 2020-01-10 2020-01-10
US202062966500P 2020-01-27 2020-01-27
US202062970491P 2020-02-05 2020-02-05
US202062984705P 2020-03-03 2020-03-03
US202062988304P 2020-03-11 2020-03-11
US202063032488P 2020-05-29 2020-05-29
US202063062377P 2020-08-06 2020-08-06

Publications (1)

Publication Number Publication Date
ECSP22026797A true ECSP22026797A (es) 2022-05-31

Family

ID=74852729

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202226797A ECSP22026797A (es) 2019-09-06 2022-04-05 Composiciones y métodos para el tratamiento de infecciones virales

Country Status (18)

Country Link
US (4) US20210220478A1 (es)
EP (1) EP4025256A4 (es)
JP (2) JP7667139B2 (es)
KR (1) KR20220088527A (es)
CN (2) CN114980933B (es)
AU (2) AU2020342649B2 (es)
CA (1) CA3153359A1 (es)
CL (1) CL2022000531A1 (es)
CO (1) CO2022003078A2 (es)
CR (1) CR20220138A (es)
EC (1) ECSP22026797A (es)
IL (1) IL290792B2 (es)
MX (1) MX2022002728A (es)
PE (1) PE20221443A1 (es)
PH (1) PH12022550505A1 (es)
TW (1) TWI861205B (es)
WO (1) WO2021046549A1 (es)
ZA (1) ZA202203681B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210079278A (ko) 2018-09-06 2021-06-29 시다라 세라퓨틱스, 인코포레이티드 바이러스 감염의 치료를 위한 조성물 및 방법
TWI861205B (zh) 2019-09-06 2024-11-11 美商席達拉醫療有限公司 用於治療病毒感染之組合物及方法
MX2022008901A (es) * 2020-01-24 2022-08-16 Regeneron Pharma Conjugados de proteinas-compuestos antivirales.
US20230364251A1 (en) 2020-08-06 2023-11-16 Cidara Therapeutics, Inc. Methods for the synthesis of protein-drug conjugates
CN116367866A (zh) 2020-08-06 2023-06-30 奇达拉治疗公司 蛋白质-药物偶联物的合成方法
WO2022192685A1 (en) 2021-03-11 2022-09-15 Cidara Therapeutics, Inc. Protein-drug conjugates for antiviral therapy
CN118678970A (zh) * 2021-12-30 2024-09-20 苏州爱科百发生物医药技术有限公司 用于预防和治疗病毒感染的偶联物及其用途
CA3261323A1 (en) * 2022-07-05 2024-01-11 Cidara Therapeutics, Inc. FC CONJUGATES INCLUDING A CD73 INHIBITOR AND THEIR USES
CN119215189A (zh) 2023-06-29 2024-12-31 上海爱科百发生物医药技术股份有限公司 用于预防和治疗病毒感染的偶联物及其用途
WO2025064869A2 (en) * 2023-09-20 2025-03-27 Cidara Therapeutics, Inc. Compositions and methods for the treatment of cancer
IL328897A (en) * 2023-12-08 2026-08-01 Suzhou Renolynx Therapeutics Co Ltd Antiviral bracelet
WO2025157263A1 (zh) * 2024-01-26 2025-07-31 浙江养生堂天然药物研究所有限公司 偶联物及其制备方法和用途
WO2025230581A1 (en) * 2024-05-02 2025-11-06 Cidara Therapeutics, Inc. Fc conjugates and uses thereof
WO2026055183A1 (en) * 2024-09-03 2026-03-12 Vir Biotechnology, Inc Antiviral compositions and methods of using the same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000068986A (ko) 1996-11-14 2000-11-25 리차드웨드레이 신규 용도 화합물 및 그 제조방법
US6495580B1 (en) 1998-01-29 2002-12-17 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
AUPP913999A0 (en) 1999-03-12 1999-04-01 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
EP1418175A1 (en) 1999-06-28 2004-05-12 Janssen Pharmaceutica N.V. Respiratory syncytial virus replication inhibitors
AUPR001000A0 (en) * 2000-09-08 2000-10-05 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AUPR879701A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
US8202896B2 (en) 2002-08-09 2012-06-19 Microdose Therapeutx, Inc. Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
RU2470668C2 (ru) 2005-08-19 2012-12-27 Эндосайт, Инк. Конъюгаты лиганда с несколькими лекарственными средствами
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
DK2568976T3 (en) 2010-05-10 2016-01-11 Academia Sinica Zanamivir-phosphonate congener with the anti-influenza activity, and determining the sensitivity oseltamivir in influenza viruses
CN102958933B (zh) 2010-06-24 2016-02-03 吉里德科学公司 作为抗病毒药的吡唑并[1,5-a]嘧啶类
EP3415528B1 (en) 2011-04-13 2021-05-26 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
US8871756B2 (en) 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
WO2014047357A1 (en) 2012-09-21 2014-03-27 The Regents Of The University Of California Modified fc polypeptides, fc conjugates, and methods of use thereof
AU2013334001B2 (en) 2012-10-16 2017-07-20 Janssen Sciences Ireland Uc RSV antiviral compounds
PL2970422T3 (pl) 2013-03-15 2018-09-28 F.Hoffmann-La Roche Ag Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
MX2016001855A (es) 2013-08-12 2016-05-24 Hoffmann La Roche Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.
TWI671299B (zh) 2014-04-14 2019-09-11 愛爾蘭商健生科學愛爾蘭無限公司 作為ｒｓｖ抗病毒化合物之螺脲化合物
WO2017046625A1 (en) 2015-06-25 2017-03-23 Cube Biotech Gmbh New chelators for affinity purification of recombinant proteins
WO2018006063A1 (en) 2016-07-01 2018-01-04 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections
US20230190950A1 (en) * 2017-01-06 2023-06-22 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections
KR20210079278A (ko) 2018-09-06 2021-06-29 시다라 세라퓨틱스, 인코포레이티드 바이러스 감염의 치료를 위한 조성물 및 방법
EP3982994A4 (en) 2019-06-13 2023-10-04 Cidara Therapeutics, Inc. Compositions and methods for the treatment of respiratory syncytial virus
CN114401731A (zh) 2019-06-13 2022-04-26 奇达拉治疗公司 用于治疗人类免疫缺陷病毒的组合物及方法
TWI861205B (zh) * 2019-09-06 2024-11-11 美商席達拉醫療有限公司 用於治療病毒感染之組合物及方法
WO2022192685A1 (en) * 2021-03-11 2022-09-15 Cidara Therapeutics, Inc. Protein-drug conjugates for antiviral therapy

Also Published As

Publication number Publication date
WO2021046549A1 (en) 2021-03-11
PH12022550505A1 (en) 2023-08-23
EP4025256A4 (en) 2023-12-13
JP2022546609A (ja) 2022-11-04
CL2022000531A1 (es) 2022-10-28
CO2022003078A2 (es) 2022-07-08
US11510992B1 (en) 2022-11-29
AU2025263868A1 (en) 2025-11-27
IL290792B1 (en) 2026-04-01
JP2025108559A (ja) 2025-07-23
EP4025256A1 (en) 2022-07-13
CN120168655A (zh) 2025-06-20
ZA202203681B (en) 2023-11-29
AU2020342649A1 (en) 2022-03-24
US20210220478A1 (en) 2021-07-22
CN114980933B (zh) 2025-01-07
WO2021046549A8 (en) 2021-05-20
MX2022002728A (es) 2022-08-04
TW202122117A (zh) 2021-06-16
US12427200B2 (en) 2025-09-30
IL290792A (en) 2022-04-01
CN114980933A (zh) 2022-08-30
NZ785415A (en) 2024-07-26
CA3153359A1 (en) 2021-03-11
CR20220138A (es) 2022-07-28
US20260108618A1 (en) 2026-04-23
US20230398226A1 (en) 2023-12-14
IL290792B2 (en) 2026-08-01
KR20220088527A (ko) 2022-06-27
AU2020342649B2 (en) 2025-08-07
JP7667139B2 (ja) 2025-04-22
BR112022004058A2 (pt) 2022-05-31
TWI861205B (zh) 2024-11-11
PE20221443A1 (es) 2022-09-21

Similar Documents

Publication Publication Date Title
CO2022003078A2 (es) Composiciones y métodos para el tratamiento de infecciones virales
ECSP21023859A (es) Composiciones y métodos para el tratamiento de infecciones virales
CY1124507T1 (el) Νεος αναστολεας μεκ για τη θεραπευτικη αγωγη των ιικων και βακτηριακων λοιμωξεων
MX2019009443A (es) Metodos para tratar la influenza.
UY37961A (es) Nuevas y altamente activas indolo-2-carboxamidas sustituidas con pirazolo-pirimidina activas contra el virus de la hepatitis b (vhb)
MX2022000453A (es) Compuestos útiles para tratar infecciones por virus de influenza.
UY37962A (es) Nuevas y altamente activas indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb)
AR111495A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CL2020001944A1 (es) Proteínas de fusión fc il-22 y métodos de uso.
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
CL2024001715A1 (es) Anticuerpo aislado que se une a la proteína e del virus del dengue; y uso.
CL2020000487A1 (es) Agentes antivirales contra la hepatitis b.
UY35362A (es) Compuestos terapéuticos
EA202091769A1 (ru) Вакцины против вируса гриппа и пути их применения
ES2682981T3 (es) Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas
MX383124B (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus.
DOP2020000160A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
MX2024002581A (es) Lou064 para el tratamiento de la esclerosis multiple.
CO2018005983A2 (es) Compuestos de isoindol
CL2024000091A1 (es) Anticuerpos y fragmentos de unión al antígeno antiglicoproteína de la espícula de sars-cov-2
MX363464B (es) Vacunas contra influenza h5.
MX2017016437A (es) Metodos de purificacion y/o inactivacion viral.
DOP2017000246A (es) Polipéptidos dirigidos a la fusión de vih
MX2015012399A (es) Conjugado de peptidos inmunogenicos y metodo para inducir una respuesta a un anticuerpo terapeutico anti-influenza con los mismos.
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano